RUNX1 and Miyoshi myopathy: To achieve this goal, it is also important to develop the relevant in vitro cellular and patient-derived (PD) xenograft models of RUNX1-FPD and FPD-MM, which can be utilized for testing novel targeted therapies for FPD-MM.